Join the 'Pneumococcal Disease Prophylaxis' group to help and get support from people like you. How it works
Pneumococcal Disease Prophylaxis Blog
| Tweet |
Doctors in a Bind When Parents Want to Delay, Skip Vaccines
Posted 28 Nov 2011 by Drugs.com
MONDAY, Nov. 28 – Mistrust of childhood vaccines is causing some parents to request "alternative" schedules from doctors, either delaying or skipping some shots. And a new study suggests that most pediatricians are willing to go along with these requests – up to a point. "Parents seem to be regularly requesting alternative childhood immunization schedules," noted co-author Dr. Douglas John Opel, an acting assistant professor in the University of Washington's department of pediatrics. However, he added, "there needs to be more research into the effectiveness and safety of these schedules." The report is published in the Nov. 28 online edition of Pediatrics. The issue of parents ignoring standard guidelines on childhood vaccination schedules is worrying to many experts. One study, published in the November issue of Pediatrics, found that more than one in 10 parents in the United States ... Read more
Related support groups: Pneumonia, Meningitis, Measles Virus Vaccine, Pneumococcal 7-Valent Vaccine, Boostrix (Tdap), Vaccination and Prophlaxis, Pneumococcal Disease Prophylaxis, Meningitis -- Pneumococcal, Prevnar, Tripedia (DTaP), Meningococcal Meningitis Prophylaxis, Meningitis -- Meningococcal, Decavac, ProQuad, Pneumococcal 13-valent Conjugate Vaccine
Vaccine Now Misses Many Pneumococcal Infections in Kids
Posted 21 Apr 2010 by Drugs.com
WEDNESDAY, April 21 – The advent in 2000 of the PCV7 vaccine to battle bacteria that causes pneumonia, meningitis and sepsis (blood infection) in children has caused notable changes in strains that cause these illnesses, researchers report. Most worrisome is the recent spread of strains not covered by the vaccine, the team aid. Immunizations with the PCV7 vaccine is now recommended for all children before the age of 2. American researchers found that the most common cause of invasive pneumococcal infections is now a strain called serotype 19A, which is not covered by the PCV7 vaccine. The studies also found a rise in infections caused by antibiotic-resistant pneumococci. One study, an analysis of 2001-07 data by Boston University researchers, revealed that only 15 percent of serious pneumococcal infections in Massachusetts were caused by one of the seven strains covered by the PCV7 ... Read more
Related support groups: Pneumococcal 7-Valent Vaccine, Prevnar, Pneumococcal Disease Prophylaxis
Young Kids to Benefit From Broader Pneumococcal Vaccine
Posted 11 Mar 2010 by Drugs.com
THURSDAY, March 11 – The recent approval of a new, more broadly effective pneumococcal vaccine (PCV13) for young children could greatly reduce the prevalence of pneumococcal disease in that age group, a new government report suggests. On Feb. 24, the U.S. Food and Drug Administration approved PCV13 and the Advisory Committee on Immunization Practices recommends the vaccine for all children aged 2 to 59 months and children with chronic illnesses who are younger than 71 months. Streptococcus pneumoniae is a major cause of bacteremia, meningitis and pneumonia worldwide, according to the report. Since 2000, vaccination of infants with the 7-valent pneumococcal conjugate vaccine (PCV7) has significantly reduced rates of invasive pneumococcal disease in the United States. However, there's been an increase in infections caused by pneumococcal strains not covered by PCV7. PCV13 – which ... Read more
Related support groups: Pneumococcal Disease Prophylaxis
FDA Approves Prevnar 13 Pneumococcal Disease Vaccine
Posted 25 Feb 2010 by Drugs.com
SILVER SPRING, Md., Feb. 24 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new vaccine extends the protection to six additional types of the disease-causing bacteria. Prevnar 13 is approved for the prevention of invasive disease caused by 13 different serotypes of the bacterium Streptococcus pneumoniae. It also is approved for the prevention of otitis media caused by the seven serotypes shared with Prevnar. The bacterium can cause infections of the blood, middle ear, and the covering of the brain and spinal cord, as well as pneumonia. "Although the rates of ... Read more
Related support groups: Pneumococcal Disease Prophylaxis
Ask a Question
You may also be interested in...
Related Condition Support Groups
Related Drug Support Groups
pneumococcal 7-valent vaccine, Prevnar, Prevnar 13, pneumococcal 23-polyvalent vaccine, pneumococcal 13-valent conjugate vaccine